Seres Therapeutics Announces Upcoming Conference Call
CAMBRIDGE, Mass. — Seres Therapeutics, Inc. (NASDAQ: MCRB), a prominent player in the live biotherapeutics sector, is gearing up to share its third quarter 2024 financial results. Scheduled for November 13, 2024, at 8:30 a.m. ET, the live audio webcast and conference call will allow stakeholders to gain insight into the company’s financial performance and strategic updates.
How to Access the Event
Interested parties can participate in the conference call by calling 800-715-9871 for domestic inquiries or 646-307-1963 for international connections, using conference ID number 5051385. For a more visual engagement, attendees can join the live webcast by heading over to the “Investors and News” section of the official Seres Therapeutics website.
Replay Availability
A recording of the webcast will be accessible on the Seres Therapeutics website, typically available about two hours post-event and will remain archived for roughly 21 days, offering investors and interested individuals a chance to catch up on the latest updates they may have missed.
Understanding Seres Therapeutics
Seres Therapeutics, Inc. (NASDAQ: MCRB) stands at the forefront of innovation in the biotherapeutics landscape. The company is dedicated to enhancing patient outcomes, particularly for those in medically vulnerable populations, through its pioneering work with live biotherapeutics. An exciting achievement has been the successful development of VOWST™, marking it as the first FDA-approved orally administered microbiome therapeutic, now in the hands of Nestlé Health Science following its acquisition in September 2024.
Current Pipeline Developments
Moreover, the company is progressing with SER-155, which has shown promising results in a clinical trial involving allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) patients. This treatment has significantly reduced bloodstream infections and related complications compared to traditional placebo treatments. The innovative approach that Seres combines with its other developmental programs aims to tackle various disease-relevant pathways and utilizes standard clonal cell banks through single-strain cultivation techniques instead of relying on the donor-sourced production process previously used for VOWST.
Future Product Goals
Seres Therapeutics is committed to furthering its mission by advancing additional cultivated oral live biotherapeutics targeted at medically vulnerable segments, including patients suffering from chronic liver disease, those undergoing cancer treatments that cause neutropenia, and individuals needing solid organ transplants. The company's exploration and dedication to novel treatments promise to push the boundaries in therapeutic care for these vulnerable populations.
Investor Relations Contact
For inquiries regarding investments and media relations, interested parties can reach out via email at IR@serestherapeutics.com. Carlo Tanzi, Ph.D., from Kendall Investor Relations, is ready to assist with any related inquiries. You can also contact him directly at ctanzi@kendallir.com.
Frequently Asked Questions
What is the purpose of the upcoming conference call?
The conference call aims to discuss Seres Therapeutics' third quarter 2024 financial results and share notable business updates.
When will the conference call take place?
The call is scheduled for November 13, 2024, at 8:30 a.m. ET.
How can I access the live audio webcast?
Participants can join the live webcast by visiting the “Investors and News” section of the Seres Therapeutics website.
What recent achievement has Seres Therapeutics noted?
Seres succeeded in developing VOWST™, the first FDA-approved orally administered microbiome therapeutic, now sold to Nestlé Health Science.
What is SER-155 and its significance?
SER-155 is being developed to address complications in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation, showing a significant reduction in bloodstream infections.
